Previous studies documented the ability of quinazoline-based a1-adrenoceptor antagonists to induce apoptosis in prostate cancer cells via an a1-adrenoceptor-independent mechanism. In this study we investigated the molecular events initiating this apoptotic effect. Since transforming growth factor-b1 (TGF-b1) mediates prostate epithelial cell apoptosis, we hypothesised that the activation of the TGF-b1 pathway underlies the quinazoline-based apoptotic effect in prostate cancer cells. Treatment of the androgenindependent human prostate cancer cells PC-3 with doxazosin resulted in a strong caspase-3 activation within 24 h, whereas tamsulosin, a sulphonamide-based a1-adrenoceptor antagonist, had no significant apoptotic effect against prostate cancer cells. To identify the molecular components involved in this quinazoline-mediated apoptosis, cDNA microarray analysis of PC-3 prostate cancer cells treated with doxazosin (3 h) was performed. Induced expression of several genes was observed including p21 WAF-1 and IkBa (inhibitor of NF-kB alpha). Relative quantitative reverse transcription -polymerase chain reaction analysis revealed induction of several TGF-b1 signalling effectors: Induction of mRNA for Smad4 and the TGF-b1-regulated apoptosis-inducing transcription factor TGF-b1-inducible early gene (TIEG1) was detected within the first 6 h of doxazosin treatment. Upregulation of IkBa at both the mRNA and protein level was also detected after 6 h of treatment. Furthermore, doxazosin resulted in a considerable elevation in Smad4 and TIEG protein expression (6 h). A 'latent' increase in TGF-b mRNA expression was detected after 48 h of treatment. These findings suggest that the quinazoline-based doxazosin mediates prostate cancer apoptosis by initially inducing the expression of TGF-b1 signalling effectors and subsequently IkBa. The present study provides an initial insight into the molecular targets of the apoptotic action of quinazolines against prostate cancer cells.
Prostate cancer continues to afflict many thousands of American males and is the cause of approximately 30 000 deaths per year (Greenlee et al, 2000) . Although therapeutic modalities such as androgen ablation and radical prostatectomy are considered curative for localised disease, no treatment for metastatic prostate cancer is available, which shows a significant increase in length of life (Raghavan, 1988; Crawford et al, 1989; Catalona et al, 1993) . The therapeutic significance of apoptosis in the treatment of prostate cancer emerges from evidence suggesting that like normal prostate epithelial cells, prostate cancer cells maintain sensitivity to androgens and undergo apoptosis in response to androgen withdrawal (Isaacs, 1994; . Androgen-independent prostate cancer cells still contain the apoptotic machinery and can undergo apoptosis in response to hormone-independent approaches (Bruckheimer and Kyprianou, 2000) . Reactivation of cell death pathways in prostate cancer cells represents a powerful approach for pharmacological intervention, and consequently targeting the apoptotic signalling in prostate cells has been the focus of numerous investigations (Bruckheimer and Kyprianou, 2000) .
A class of pharmacological agents, the a1-adrenoceptor antagonists, originally used as antihypertensive agents (Young and Brogden, 1988) , have been safely used as standard medical therapy for benign prostatic hyperplasia (BPH) and the long-term relief of lower urinary tract symptoms (LUTS) (Caine, 1988; Kirby, 1996) . Growing evidence suggests that two of these clinically used a1-adrenoceptor antagonists, doxazosin and terazosin, that share a similar chemical structure, the quinazoline nucleus (Figure 1 ), exert a potent apoptotic effect against prostate cancer cells ( Kyprianou and Benning, 2000) , via an a1-adrenoceptor-independent mechanism (Benning and Kyprianou, 2002) and suppression of tumour vascularity (Keledjian et al, 2001) .
Apoptosis induction by androgen withdrawal in normal and hormone-dependent malignant prostate involves the transforming growth factor-b1 (TGF-b1) signalling pathway (Kyprianou and Isaacs, 1989) . Recent immunohistochemical analysis of BPH tissue revealed an increase in TGF-b1 expression but no change in TGFbII receptor (TbRII) in patients who had undergone treatment with the clinically used quinazoline-based a1-adrenoceptor antagonist terazosin (Glassman et al, 2001) . The TGF-b1 signalling system normally functions to inhibit proliferation and induce apoptosis of epithelial and endothelial cells ; its signal transduction pathway involves the receptor-mediated activation by phosphorylation of the intracellular effectors, Smad2, Smad3 and Smad4, and their translocation to the nucleus where they regulate gene transcription (Massague, 2000) . Expression and Revised 6 March 2003; accepted 12 March 2003 activation of these intracellular effectors of the TGF-b1 pathway are critical to the execution of the apoptotic process (DeCaestecker et al, 2000) . An inhibitory regulator of TGF-b1 signalling, Smad7, (Whitman, 1997 ) is regulated by TGF-b1 specifically via Smad3 and Smad4 indicating a negative feedback mechanism (Hayashi et al, 1997) . Smad7 is induced during apoptosis of prostate epithelial cells (Brodin et al, 1999) and has recently been shown to sensitise other cell types to apoptosis Schiffer et al, 2001) .
The TGF-b1-inducible early gene (TIEG1) is another factor that induces apoptosis in breast, lung and kidney cells (Tachibana et al, 1997; Chalaux et al, 1999; Hefferan et al, 2000) , potentially by downregulating the antiapoptotic protein bcl-2 (Chalaux et al, 1999) .
This study aimed to identify the molecular mechanism underlying the apoptotic action of quinazoline-based a1-adrenoceptor antagonists against prostate cancer cells. Our findings demonstrate that doxazosin induces the apoptotic signalling potentially via the activation of TGF-b1 pathway with a potential involvement of NFkB nuclear effectors.
MATERIALS AND METHODS

Materials
The a1-adrenoceptor antagonists used in this study were generously provided by the following pharmaceutical companies: doxazosin (Cardura; Doxazosin Mesylate) was provided by Pfizer Pharmaceuticals (New York, NY, USA); terazosin (Hytrin; terazosin hydrochloride) was obtained from Abbott Laboratories (Abbot Park, IL, USA); and tamsulosin (Flomax) was provided by Yamanouchi Pharmaceuticals (Tokyo, Japan).
Cell culture
The human prostate cancer PC-3 cell line was obtained from the American Type Tissue Culture Collection (Rockville, MD, USA). PC-3 cells were routinely maintained in RPMI (Life Technologies, Gaithersburg, MD, USA), containing fetal bovine serum (FBS) (10%) and antibiotics.
cDNA microarray analysis
Microarray analyses were performed according to the manufacturer's instructions. Microarray filters (SuperArray Inc., Bethesda, MD, USA) consisting of 23 markers for specific signal transduction pathways including mitogenic (Egr-1, c-fos), antiproliferative (p19, p21 Waf1 ) and p53 (mdm2, bax) pathways were used. Briefly, total RNA was isolated from both untreated PC-3 cells (control) or cells treated with doxazosin (25 mM) for 3 h. Biotin-labelled probes were made from the isolated control and test RNA. The filters were exposed to film and the genes were visualised as dots. A score for the relative intensities of these genes was calculated after densitometric analysis using the Scion Image program (National Institutes of Health, USA, http://rsb.info.nih.gov/scion-image/). Equal probe hybridisation to each filter was confirmed by b-actin and GAPDH internal controls. Results represent the mean of two independent experiments.
RT -PCR analysis
Exponentially growing cultures of PC-3 cells were treated with doxazosin (25 mM) for 6, 12, 24 and 48 h. Total cellular RNA was isolated from untreated control and treated cells using the Trizol reagent. RNA (1 mg) was reverse transcribed into cDNA using the SuperScript II system (GIBCO BRL, Grand Island, NY, USA) in a thermocycler (Biometra, Göttingen, Germany). The RNA, dNTPs and random hexamers were incubated for 5 min at 651C followed by the addition of the buffer, reverse transcriptase (RT), Rnase inhibitor and MgCl 2 , and the reaction mixture was incubated at 421C for 50 min. The polymerase chain reaction for TGFb, TbRII, Smad4, Smad7 and TIEG was performed in a total volume of 25 ml containing 0.5 ml RT reaction mixture, 50 mM KCl, 10 mM Tris-HCl, 2 mM MgCl 2 , 2.5 U Taq DNA polymerase, 0.15 mM of each forward and reverse primer, and distilled water. The following cycling conditions were used for 37 cycles in a thermal cycler (PerkinElmer Gene Amp 2400 Wellesley, MA, USA or Biometra T Gradient, Gottingen, Germany): initial denaturation, 5 min at 941C; denaturation 30 s at 941C; annealing 30 s at 551C and elongation, 30 s at 721C. The programme was followed by a final elongation step for 5 min at 721C. Control reactions were performed for each series by omitting either the mRNA or RT. For qualitative analysis, RT -PCR products were electrophoresed through agarose gels (2.5%) and visualised with ethidium bromide staining.
Relative quantitative RT -PCR was performed with the QuantumRNA TM 18S Internal Standards kit (Ambion Austin, TX, USA) according to the protocol recommended by the manufacturer with some modifications. Briefly, the ratio of 18S rRNA primers to competimers that resulted in a PCR product approximately equal to abundance of the specific gene at the selected number of cycles of amplification was determined. The recommended 18S primer: competimer ratios of 1 : 9, 2 : 8 and 3 : 7 were tested and a 1 : 9 ratio resulted in an approximately equal ratio for all four products. Relative quantitative RT -PCR was subsequently performed using RNA from untreated control and doxazosin-treated cells. Samples (10 ml) of PCR products were subjected to electrophoretic analysis on agarose gels (1.8% w v À1 ) and bands were visualised with SYBR Gold nucleic acid stain (Molecular Probes, Eugene, OR, USA). Densitometric analysis was performed using a UVP Bioimaging System (Upland, CA, USA). The expression profile of the various genes after doxazosin treatment was analysed in three independent experiments.
Western blot analysis
Cells from untreated control and treated cells (with either doxazosin or tamsulosin) were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.5% deoxycholic acid: 1% Nonidet P40 Figure 1 Chemical structure of a1-adrenoceptor anatagonists. The quinazoline nucleus is shared by the two quinazoline-based a1-adrenoceptor antagonists doxazosin and terazosin, but not by the methoxysulphonamide-derived a1-adrenoceptor antagonist tamsulosin.
with 1 mM PMSF). Total cell lysates (30 -50 mg) were subjected to sodium dodecyl sulphate (SDS) -polyacrylamide gel electrophoresis, then transferred onto Hybond-P membranes (Amersham Pharmacia Biotech., Piscataway, NJ, USA). Membranes were blocked with 5% dry milk in TBS-T (Tris-buffered-saline containing 0.05% Tween-20) for 1 h at room temperature, and were subsequently incubated with the primary antibody (18 h at 41C). Expression of specific proteins was assessed using the respective antibodies: Smad4 (Oncogene, Boston, MA, USA), caspase-3 (Pharmigen, San Diego, CA, USA), IkBa (Santa Cruz Biotechnology, Santa Cruz, CA, USA), TIEG1 (a generous gift from Dr R Urrutia, Mayo Clinic, Rochester, MN, USA) and a-actin was from Calbiochem #CP01; San Diego, CA, USA). Following incubation with the respective primary antibody, membranes were incubated with species-specific horseradish peroxidase (HRP)-labelled secondary antibodies (1 h at room temperature). Membranes were subsequently incubated with the enhanced chemiluminescence system (ECL, Amersham Life Sciences RPN 2108) and autoradiographed using X-ray film (Amersham Pharmacia Biotech). Densitometric analysis was performed using the Scion Image Program (National Institutes of Health, USA, http://rsb.info.nih.-gov/scion-image). Bands were normalised to a-actin expression and shown as fold changes relative to untreated controls.
ELISA
The procedure was essentially performed according to the manufacturer's instructions (Promega, WI, USA). Briefly, a 96-well plate was coated with TGF-b1 antibody in carbonate coating buffer and incubated overnight at 41C. Supernatants derived from PC-3 cells after various periods of doxazosin treatment were added to the respective wells (0, 3, 6, 9 and 24 h). Secondary anti-TGF-b1 (1 : 1000 dilution) was added to the samples and incubated for 2 h. Plates were subsequently washed and TGF-b1 -horseradish peroxidase (HRP) conjugate was added. Upon termination of the reaction, the absorbance was read at A 450 .
RESULTS
Previous studies have demonstrated that the piperizidinyl quinazoline-based a1-adrenoceptor antagonists doxazosin and terazosin ( Figure 1 ) induce apoptosis in prostate cancer cells, whereas the methoxysulphonamide-derived a1-adrenoceptor antagonist tamsulosin had no apoptotic function (Kyprianou and Benning, 2000) . Caspases as apoptosis executioners upon sequential activation can cleave protein substrates leading to apoptotic cell death (Cohen, 1997) . To determine the involvement of the caspase cascade in a1-adrenoceptor antagonist-mediated apoptosis and the observed differences in apoptotic capability between these two structurally dissimilar drugs, we investigated the activation of caspase-3 in prostate cancer cells treated with either doxazosin or tamsulosin. Western blotting revealed the temporal induction of caspase-3 (17 kDa) in doxazosin-treated cells after 9 h, an effect that was maintained up to 24 h (Figure 2A) . The activated form of caspase-3 was not detected in tamsulosin-treated prostate cancer cells ( Figure 2B) , consistent with the inability of this compound to induce apoptosis (Kyprianou and Benning, 2000) .
In order to determine the early alterations in gene expression that may be causally involved in quinazoline-induced apoptosis, cDNA microarray analyses were performed. RNA was isolated from cultures of PC-3 cells, untreated control or following treatment with doxazosin (25 mM) for 3 h. Table 1 summarises the expression profile of doxazosin-regulated genes in human prostate cancer cells. Out of the 23 genes examined, eight were upregulated by at least two-fold, whereas four were downregulated. Our array analysis revealed a dramatic induction of two genes within 3 h of doxazosin treatment p21 (seven-fold) and IkBa (ninefold). Interestingly, both these genes are inducible by TGF-b1 (DeCaestecker et al, 2000; Massague, 2000) , suggesting a potential reactivation of this signalling pathway by doxazosin. Two other apoptosis-regulating genes were also moderately induced, the fas ligand (43-fold) and hsf1 (four-fold).
Since induced expression of IkBa was detected within 3 h of doxazosin treatment (Table 1) , we examined the mRNA and protein expression profile in PC-3 cells over a 48-h treatment period with the drug. The RT -PCR analysis revealed a significant doxazosin-mediated induction in mRNA expression within 6 h (approx. 100% relative to untreated control cells); a maximum increase in IkBa mRNA levels was detected after 24 h and at 48 h of treatment a moderate decrease was observed ( Figure 3A) . A parallel temporal elevation of IkBa protein expression reaching a maximum after 24 h of doxazosin treatment was detected by Western blot analysis ( Figure 4A ).
To gain a further insight into the mechanism underlying quinazoline-induced apoptosis, the temporal expression of several genes involved in TGF-b1-mediated apoptosis, that is, the ligand TGF-b, its critical receptor TbRII receptor, the intracellular effectors Smad4 and Smad7, and the nuclear factor TIEG1 was evaluated. Since increased TGF-b1 protein expression is associated with apoptosis (Glassman et al, 2001) , we first examined the expression profile of TGF-b1 in doxazosin-treated prostate cancer cells. A significant increase in TGF-b1 mRNA expression were detected within the first 12 h of doxazosin treatment ( Figure 3B ). This mRNA induction for TGF-b resulted in a significant increase in the levels of active TGF-b1 protein produced by PC-3 prostate cancer cells (Po0.05). After 24 h of exposure to doxazosin, there was a decline in TGF-b1 levels to baseline values ( Figure 5 ). No changes in the TbRII receptor mRNA expression by PC-3 cells were observed in response to doxazosin (data not shown). A marked induction in TIEG1 ( Figure 3C ) and Smad4 ( Figure 3D ) mRNA levels was observed within 6 h of treatment (65% increase), while there was a transient decrease in Smad7 mRNA expression for 24 h of doxazosin exposure, and it was subsequently followed by an upregulation by 48 h compared to the untreated control PC-3 cells ( Figure 3E ). Smad4 is an important regulator of TGF-b1 signalling and apoptosis in a variety of cell lines (Kim et al, 1996; Liu et al, 1997) . Considering that Smad4 mRNA is upregulated, we investigated the effect of doxazosin on Smad4 protein levels. As shown in Figure 4C , there was an increase in Smad4 protein expression in response to doxazosin and this elevation was maintained throughout all treatment periods examined (up to 24 h), a pattern that temporally correlates with the mRNA expression profile ( Figure 3D ).
DISCUSSION
The ability of quinazoline-derived a1-adrenoceptor antagonists to induce apoptosis in human prostate cancer cells via an a1-adrenoceptor-independent mechanism has been established (Kyprianou and Benning, 2000; Benning and Kyprianou, 2002) . The present study focused on dissecting the molecular mechanism underlying this action. Our findings demonstrate that caspase-3 was activated in response to doxazosin and not tamsulosin, evidence confirming the apoptotic nature of the action of quinazoline-derived a1-adrenoceptor antagonists against prostate cell growth. This induction was first evident within 9 h of treatment and was maintained up to 24 h, a pattern that temporally correlates -24 h). Cell lysates were isolated from treated and untreated cells and subjected to Western blot analysis. Protein expression of IkBa (A), TIEG1 (B) and Smad4 (C) were examined by Western blotting using the respective antibodies as described in 'Materials and Methods'. Expression of a-actin was used as a normalising control and fold changes for each specific protein relative to untreated controls (after normalisation to a-actin expression) are shown. with the morphological manifestations of apoptosis in prostate cancer cells following doxazosin treatment (Kyprianou and Benning, 2000) . TGF-b1 has recently been shown to activate caspase-3 to induce apoptosis in the NRP-154 prostate epithelial cell line (Chipuk et al, 2001) , evidence supporting our hypothesis that doxazosin may activate apoptosis of prostate cancer cells through TGF-b1 signalling. Doxazosin resulted in a 'latent' induction of TGF-b1 mRNA expression that was subsequent to a moderate increase in the active TGF-b1 levels by prostate cancer cells PC-3 (after 24 h of treatment). While a similar pattern has been exhibited by apoptotic T-cells with an enhanced release of active TGF-b1 without major changes in the mRNA expression (Chen et al, 2001) , one may also consider the possibility that the observed upregulation of TGF-b mRNA in prostate cancer cells could be a consequence of doxazosin-induced apoptosis. The lack of induction of TbRII expression in prostate cancer cells by doxazosin is consistent with our earlier report indicating no changes in TbRII protein levels in prostate tissue (from BPH patients) after treatment with the quinazolines (Glassman et al, 2001 ). It appears that doxazosin modulated the expression of the intracellular effectors TGF-b1 signalling pathway, Smad4 and Smad7 proteins, towards activation of the apoptotic machinery.
Microarray-based examination of doxazosin mediated-gene expression revealed the rapid upregulation of two TGF-b1-modulated genes, IkBa and p21 WAF-1 . Doxazosin-induced overexpression of IkBa may have implications for NF-kB intracellular signalling. For instance, in prostate cancer cells and metastatic melanoma cells, the blockade of NF-kB by a nondegradable dominant-negative IkBa mutant suppresses angiogenesis, invasion and metastasis (Huang et al, 2000 (Huang et al, , 2001 , and may reduce the apoptotic effects associated with NF-kB signalling (Baldwin, 1996) . These reports together with the observed upregulation of IkBa in prostate cancer cells may provide a mechanism to explain the increased apoptosis and reduced tumour vascularity in prostate cancer specimens (Keledjian et al, 2001) . Constitutive activation of NF-kB has been reported in many tumours (Baldwin, 1996) , including androgen-independent prostate cancer cells (Pajonk et al, 1999; Palayoor et al, 1999; Suh et al, 2002) and oestrogen receptor-negative breast cancer cells (Biswas et al, 2001 ). This activation of NF-kB survival signalling is believed to provide a growth advantage in androgen-independent prostate cancer cells by suppressing apoptosis and inducing cell adhesion and angiogenic potential (Huang et al, 2001; Gasparian et al, 2002) .
Smad4 is the principal intracellular effector of TGF-b1 signalling and its expression is regulated at the protein and mRNA level by doxazosin in PC-3 cells. The mechanism may involve the inhibition of Smad4 degradation, recently reported to be mediated by the oncogenic Ras pathway. Blockade of the oncogenic Ras pathway using a quinazoline-based tyrosine kinase inhibitor (TKI) PD98059 restores Smad4 expression levels and TGF-b1 signalling in vitro (Saha et al, 2001) . Upregulation of Smad4 would also facilitate the transcription of several TGF-b1-regulated genes such as Smad7 (Von Gersdorff et al, 2000) . While Smad7 is induced during androgen-withdrawal-induced apoptosis in prostate cells (Brodin et al, 1999) , Smad7 induction has also been shown to antagonise directly TGF-b1 signalling (Whitman, 1997) . Considering the evidence that Smad7-mediated apoptosis functionally involves inhibition of NF-kB nuclear signalling Schiffer et al, 2001) and in view of the present observations that IkBa is upregulated within 6 -24 h, preceding the induction of Smad7 (observed at 48 h of treatment), one may suggest that doxazosin may indeed have inhibitory effects on NF-kB signalling pathway, by inducing IkBa, an action that subsequently triggers apoptosis.
TIEG1 is an early TGF-b1 upregulated transcription factor that has been documented to regulate apoptosis in several tumour cell lines. The role of this nuclear factor has not yet been characterised in prostate growth, but it might potentially involve the activation of proapoptotic mechanisms, such as the downregulation of bcl-2 as reported in lung epithelial cells (Chalaux et al, 1999) .
The a1-adrenoceptor antagonists doxazosin and terazosin share structural similarities with particular TKIs owing to the presence of a quinazoline ring (Figure 1) . It is thus of major interest that several quinazoline-based chemicals have been demonstrated to compete with ATP binding to protein tyrosine kinases to inhibit various intracellular signalling pathways (Rewcastle et al, 1995) . The mechanism of action for quinazoline-based TKI involves prevention of the transmembrane tyrosine kinase phosphorylation by competing with the ATP-binding site on the receptor (Arteaga et al, 1997) . The presence of this component may provide additional valuable insights into the molecular mechanisms for a1-adrenoceptor antagonist-mediated apoptotic action in tumour cells (Anglin et al, 2002) . Considering this evidence, one can speculate on the potential function of the intrinsic quinazoline component to confer partial TKI activity to these drugs, a unique structural characteristic with potentially significant pharmacological dimensions that warrant further investigation. Moreover, a potential antiangiogenic effect of terazosin and doxazosin against prostate tumours has been demonstrated in both in vitro and in clinical prostate specimens (Chon et al, 1999; Keledjian et al, 2001; Keledjian and Kyprianou, 2003) . This action is believed to be mediated by quinazoline-induced anoikis and inhibition of cell invasion (Keledjian and Kyprianou, 2003) .
In conclusion, we have demonstrated that doxazosin-mediated apoptosis in prostate cancer cells involves activation of latent apoptotic machinery via effectors of TGF-b1 signalling. In addition, this initial molecular dissection revealed that an inhibitory pathway involving NF-kB is triggered by this quinazoline-based a1-adrenoceptor antagonist. Several signalling mechanisms are likely to be involved in a molecular crosstalk, such as the Smad activation and inhibition of the antiapoptotic effects of NFkB. Ongoing studies are focused on further characterisation of these pathways and the functional significance of the overexpressed genes in specimens from doxazosin-treated patients. This will provide the molecular basis for assessing the potential therapeutic significance of quinazoline monotherapy in androgenindependent prostate cancer.
